IPH4102: Potential Treatment for Cutaneous T-Cell Lymphoma

Researchers report that IPH4102, a first-in-class monoclonal antibody that targets killer cell immunoglobulin-like receptor 3DL2 (KIR3DL2), shows promising activity in relapsed or refractory cutaneous T-cell lymphoma (CTCL), a rare cancer that affects the skin. A cell surface protein, KIR3DL2 is expressed particularly strongly in patients with a form of CTCL called Sézary syndrome, which is an aggressive blood cancer. This international, first-in-human, open-label phase 1 clinical trial (NCT0259...
Continue reading

CAR T-Cell Therapy: New Treatment for Large B-Cell Lymphoma

Large B-cell lymphoma is an extremely destructive, invasive subtype of non-Hodgkin lymphoma. Often, patients with this malignancy have undergone several treatments that have not worked. New therapeutic approaches are necessary for relapsed/refractory disease. A breakthrough personalized treatment, CAR T-cell therapy may be an option for patients with relapsed/refractory large B-cell lymphoma. Patients undergo a process called leukapheresis, in which a patient's blood is collected and put through...
Continue reading

Brentuximab Vedotin Approved in Peripheral T-Cell Lymphomas

The FDA has expanded the approval of brentuximab vedotin (Adcetris®, Seattle Genetics, Inc.) in combination with chemotherapy as a first-line treatment for adults with systemic anaplastic large cell lymphoma (ALCL) and other peripheral T-cell lymphomas (PTCLs) expressing the tumor marker CD30. This is the first FDA-approved treatment for patients with newly diagnosed PTCLs. Peripheral T-cell lymphomas are a diverse group of rare non-Hodgkin lymphomas that result when the immune system's T cells ...
Continue reading

To Help Blood Cells Regenerate After Radiotherapy, "Mechanoprime" MSCs

Radiation therapy to the bone marrow destroys cancerous leukemia and lymphoma cells, but it also leaves patients susceptible to infection until their blood cells can regenerate. Researchers at the Massachusetts Institute of Technology (MIT) have found a way to speed up this regeneration by using a technique known as "mechanopriming" to enhance the ability of mesenchymal stromal cells (MSCs) to aid in the process. Mesenchymal stromal cells are stem cells capable of differentiating into a variety ...
Continue reading

Going Organic Reduces Cancer Risk

A new study has found that by dramatically reducing the risk of lymphomas and decreasing the risk of postmenopausal breast cancer, a diet that consists primarily of organic foods can lower an individual's overall risk of cancer. Cancer development has been linked to pesticide exposure, and strict regulations mean that organic foods have a much lower occurrence of pesticide residues than conventionally produced foods do. However, research concerning whether organic foods actually reduce cancer ri...
Continue reading

Subscribe

Get the latest updates delivered to your inbox!

Follow Us

Copyright © 2021 Oncology Data Advisor. All rights reserved.